Loading, Please Wait...
SAN FRANCISCO, CA and BETHESDA, Md., March 25, 2019 (GLOBE NEWSWIRE) -- Vineti, Inc., the leading software platform of record for personalized therapies, and OutcomeRx, a new division of CareMetx, LLC, a technology-enabled hub and patient services provider for pharmaceutical and biotechnology manufacturers, today announced a new alliance to build patient-centered digital and services solutions to streamline cell and gene therapies.
“Gene and cell therapies are creating miracles for patients and their families,” said Bob Dresing, CareMetx Chairman and Co-founder. “To bring these treatments to patients, OutcomeRx and Vineti will help to overcome unprecedented challenges, including the complex processes around the supply chain, getting patients treated, paying for the therapy and evaluating the patient’s health over time.”
Personalized therapeutics, such as cell and gene therapies and personalized cancer vaccines, are highly individualized medical innovations that require specialized technology solutions to ensure each patient receives and benefits from individualized drug therapy. In January, the U.S. Food and Drug Administration announced that it expects to receive more than 200 new cell and gene therapy applications per year by 2025, and to approve 10 to 20 new cell and gene treatments each year.
“Personalized therapies need to be supported by technology solutions as innovative as their science,” said Amy DuRoss, CEO and Co-founder of Vineti. “Providing large numbers of patients with personalized therapies requires a new digital foundation that supports the patient journey. Vineti is excited to be working with CareMetx’s new division, OutcomeRx, and its distinctive digital and services platform. Together, we can make a real commitment to helping patients.”
Vineti is deeply experienced in solving the supply chain challenges involved in personalized therapeutics. Its Personalized Therapy Management platform™ is the first commercial, configurable, cloud-based software solution to integrate logistics, manufacturing and clinical data for individualized gene and cell therapies. In fact, the Vineti platform makes it possible for biopharmaceutical developers to offer a simple, compliant and safe product process for each patient, while scaling from development through regulatory approval and commercialization. Vineti offers the only independent workflow orchestration platform to have been part of a successful, expedited cell therapy filing.
OutcomeRx, the new CareMetx division, combines technology products, award-winning patient services and new capabilities, such as financial products needed for gene and cell therapy.
“One patient at a time – that is what OutcomeRx is focused on,” said Mark Hansan, CareMetx President and CEO. "The alliance between CareMetx and Vineti brings two best-in-class companies together to provide a superb and seamless patient experience, while supporting the safety and accuracy of complex therapies in a rapidly changing environment. Personalized medicine will not just become the norm, but ultimately will change patient lives."
For CareMetx, this alliance is built on a foundation of personal experience and patient service. Dresing, CareMetx’s Chairman and Co-founder, served as President and CEO of the Cystic Fibrosis Foundation from 1984-1994, during which time the gene responsible for cystic fibrosis was discovered, and funding for gene therapy research began. Now, personalized cell and gene therapies are addressing a growing range of serious genetic disorders and severe diseases, including sickle cell disease, inherited anemias and cancer.
“OutcomeRx represents the culmination of our commitment over the past 30 years to advance patient advocacy and access to cutting-edge therapies,” Hansan said. “We are thrilled to partner with Vineti to wrap our technology, services and financial products around its market-leading software platform.”
Collectively, Vineti and CareMetx understand that the patient journey and distribution models of traditional pharmaceuticals will not be the same tomorrow. The Vineti-OutcomeRx solution will be offered to current and prospective CareMetx clients, as well as directly through Vineti's business development team.
About Vineti, Inc.
Vineti offers the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies. Now a fully independent company, Vineti provides its Personalized Therapy Management platform™ to integrate logistics, manufacturing and clinical data for individualized therapies to align and orchestrate the cell and gene therapy process and to improve drug product performance overall. The company is expanding rapidly, and the Vineti platform will be in use in hundreds of leading medical centers worldwide in 2019, on behalf of multiple biopharmaceutical partners. For more information, please visit www.vineti.com. Sign up to follow @vinetiworks on https://twitter.com/vinetiworks.
About CareMetx, LLC
CareMetx, LLC is a Bethesda, Maryland-based company providing technology and services to support patients in accessing and benefiting from specialty and orphan therapies. CareMetx is committed to delivering compassionate advocacy to patients, real-time decision-making data and confidence-building insight for clients. In addition to CareMetx’s core services, a new division, OutcomeRx, supports the evolving gene and cell therapy landscape. OutcomeRx will combine CareMetx’s technology suite, award-winning patient services, logistics partnerships, long-term outcomes monitoring, and financial solutions to facilitate patient access to these innovative cell and gene therapies.
Media Contact, Vineti
Director, PR and Scientific Communications
Media Contact, CareMetx